( veloping and commercializingophthalmic...)Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting,Health

    Sirion Therapeutics Reception for all ARVO attendees:


    A company update and presentation by Sirion Therapeutics' senior

    executives

    Date: Tuesday, May 8, 2007, 7:30 p.m. -- 9:00 p.m.

    Venue: Ft. Lauderdale Grande

    For additional information, contact Mary Leaper at

     or register online at

    www.siriontherapeutics.com/ARVO and use the password VISION.



    ARVO poster presentations featuring ST-601 (difluprednate):


    Preclinical Pharmacokinetics of Difluprednate Emulsion

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B741, Program Number: 2651


    Ocular Distribution and Metabolism after Instillation of Difluprednate

     Ophthalmic Emulsion in Rabbits

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B744, Program Number: 2654


    Preclinical Toxicity of Difluprednate Emulsion

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B743, Program Number: 2653


    Efficacy of Difluprednate Ophthalmic Emulsion in Preclinical Studies of

     Uveitis

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B742, Program Number: 2652


    Difluprednate Emulsion Inhibits Postoperative Inflammation in Rabbit

     Paracentesis Model

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B745, Program Number: 2655


    A Phase III, Non-Inferiority Study of Difluprednate Ophthalmic Emulsion

     (DFBA), 0.05% in the Treatment of Anterior Uveitis

    Session Date: Wednesday, May 9, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B808, Program Number: 3904


    A Phase III, Open-Label, Clinical Study of Difluprednate Ophthalmic

     Emulsion (DFBA), 0.05% in the Treatment of Severe Refractory Anteri
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic
Drug to Treat Viral Eye Infection
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of
Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into
Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to
Sustained Reductions in Blood Glucose Levels for 6 Months
Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for
Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical
Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II
Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on
Visceral Fat and Insulin Resistance at American Diabetes
Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of
Efaproxyn in Women With Brain Metastases Originating From Breast
Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and
Experimental Therapeutics